Skip to main content
OpenTrials
Completed

NCT Number: NCT06949852

Evaluation of Safety and Efficacy of Nalbuphine Versus Morphine for Postoperative Analgesia

Evaluation of safety and efficacy of Nalbuphine versus Morphine patient controlled intravenous analgesia (PCIA) for the treatment of postoperative analgesia

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Postoperative Analgesia

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Peking University First Hospital, Beijing, China

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18-65 years (inclusive), regardless of gender.
  • Weight 45-100 kg (inclusive) and BMI 18.0-30.0 kg/m² (inclusive).
  • Preoperative ASA Physical Status Class I-III.
  • Scheduled for elective general anesthesia in abdominal surgery (single incision ≥5 cm) or orthopedic surgery (limb/joint procedures); completed anesthesia recovery within 4 hours postoperatively, with NRS score ≥4, and willingness to accept protocol-defined analgesia.
  • Ability to comprehend study objectives, operate PCIA devices, and communicate effectively with investigators.
  • Female subjects must be non-pregnant, non-lactating, and agree to use contraception (including partners) for 3 months post-study.
  • Voluntary participation with signed informed consent.

Exclusion criteria

  • Known or suspected allergy/hypersensitivity to any component of the investigational product, other opioids, or contraindicated drugs specified in the protocol .
  • Neurological/psychiatric disorders including:
  • Clinically significant neurological diseases (e.g., epilepsy, cognitive impairment) .
  • History of brain injury, increased intracranial pressure, or psychiatric disorders (e.g., schizophrenia, bipolar disorder, depression, anxiety) that may interfere with safety or study assessments as judged by the investigator .
  • Cardiovascular diseases/history:
  • Severe cardiovascular conditions (NYHA Class II or higher), myocardial infarction, angina, or severe arrhythmia within the past year .
  • Abnormal 12-lead ECG findings during screening (e.g., sinus bradycardia ≤55 bpm, ≥Grade II AV block) deemed unsuitable by the investigator .
  • Resting systolic blood pressure ≥160 mmHg or <90 mmHg, diastolic ≥100 mmHg pre-surgery .
  • Intraoperative circulatory instability (e.g., hypotension, bradycardia) assessed as high-risk for trial continuation .
  • Respiratory disorders/history:
  • Bronchial asthma, high-risk respiratory depression conditions (e.g., severe COPD ≥GOLD 3, sleep apnea syndrome) .
  • Preoperative SpO2 <93% (room air) or intraoperative respiratory depression/ventilatory dysfunction deemed unsafe .
  • Paralytic ileus, biliary/pancreatic diseases within 12 months before screening .
  • Major surgery within 3 months prior to screening.
  • Acute/chronic non-surgical pain interfering with postoperative pain assessment .
  • Preoperative anemia: Hemoglobin <70 g/L or hematocrit <25% .
  • High bleeding risk:
  • Congenital bleeding disorders (e.g., hemophilia) .
  • Platelet count <0.75×LLN, PT >ULN+3s, or APTT >ULN+10s .
  • Organ dysfunction:
  • Albumin <35 g/L (untreated) .
  • Liver/kidney function abnormalities: TBIL/ALT/AST/ALP ≥1.5×ULN ; Creatinine ≥1.5×ULN or clinically significant renal impairment; Recent dialysis (within 28 days) .
  • Random blood glucose ≥11.1 mmol/L during screening (preoperative) .
  • Participation in other clinical trials with active treatment within 3 months before surgery .
  • Other conditions deemed unsuitable by the investigator for safety or protocol compliance.

Treatment and study plan

Nalbuphine hydrochloride injection

Drug

PCIA，The lockout interval is set at 10 minutes, with no background infusion.

morphine hydrochloride injection

Drug

PCIA，The lockout interval is set at 10 minutes, with no background infusion.

Primary outcomes

  1. Sum of Pain Intensity Difference over 0-48 hours(SPID48)

    Time frame: 0-48 hours

    SPID48=∑PID48×[time in hours slapsed since the previous observation], PID48 denotes the pain intensity difference at time 48 hours after the first administration relative to baseline. The pain intensity is rated using an 11-point numeric scale ranging from 0 to 10, where 0 represents "no pain" and 10 represents "the worst pain imaginable."

Secondary outcomes

  1. Sum of Pain Intensity Difference over 0-12 hours(SPID12)

    Time frame: 0-12 hours

    SPID12=∑PID12×[time in hours slapsed since the previous observation], PID12 denotes the pain intensity difference at time 12 hours after the first administration relative to baseline. The pain intensity is rated using an 11-point numeric scale ranging from 0 to 10, where 0 represents "no pain" and 10 represents "the worst pain imaginable."

  2. Sum of Pain Intensity Difference over 0-24 hours(SPID24)

    Time frame: 0-24 hours

    SPID24=∑PID24×[time in hours slapsed since the previous observation], PID24 denotes the pain intensity difference at time 24 hours after the first administration relative to baseline. The pain intensity is rated using an 11-point numeric scale ranging from 0 to 10, where 0 represents "no pain" and 10 represents "the worst pain imaginable."

  3. Sum of Pain Intensity Difference over 0-32 hours(SPID32)

    Time frame: 0-32 hours

    SPID32=∑PID32×[time in hours slapsed since the previous observation], PID32 denotes the pain intensity difference at time 32 hours after the first administration relative to baseline. The pain intensity is rated using an 11-point numeric scale ranging from 0 to 10, where 0 represents "no pain" and 10 represents "the worst pain imaginable."

  4. Total Number of PCIA Pump attempts during 0~48h

    Time frame: 0-48 hours

    The PCIA protocol was implemented as follows: For subjects with baseline NRS scores ≥4, investigators administered the first PCIA bolus to initiate analgesia.The exact time of investigator's first PCIA activation was recorded as D0-0h. PCIA Pump Settings: Experimental Group: 2 mg per demand dose (2 mL/dose); Control Group: 1 mg per demand dose (2 mL/dose); Lockout Interval: 10 minutes. Background Infusion: None. Subsequent Analgesia Management: Following initial activation, subjects self-administered additional PCIA doses as needed based on pain levels. Subsequent PCIA Use: Subjects self-administer additional PCIA doses as needed based on pain levels. PCIA Discontinuation & Data Collection: At 48 hours (±20 min) after the first study drug administration (or upon early withdrawal), study staff will: pause and disconnect the PCIA pump, Record: total number of PCIA presses, number of effective presses and total dosage of study drug delivered via PCIA

  5. Number of Effective Deliveries during 0~48h

    Time frame: 0-48 hours

    The PCIA protocol was implemented as follows: For subjects with baseline NRS scores ≥4, investigators administered the first PCIA bolus to initiate analgesia.The exact time of investigator's first PCIA activation was recorded as D0-0h. PCIA Pump Settings: Experimental Group: 2 mg per demand dose (2 mL/dose); Control Group: 1 mg per demand dose (2 mL/dose); Lockout Interval: 10 minutes. Background Infusion: None. Subsequent Analgesia Management: Following initial activation, subjects self-administered additional PCIA doses as needed based on pain levels. Subsequent PCIA Use: Subjects self-administer additional PCIA doses as needed based on pain levels. PCIA Discontinuation & Data Collection: At 48 hours (±20 min) after the first study drug administration (or upon early withdrawal), study staff will: pause and disconnect the PCIA pump, Record: total number of PCIA presses, number of effective presses and total dosage of study drug delivered via PCIA

  6. Total Delivered Dose during 0~48h

    Time frame: 0-48 hours

    The PCIA protocol was implemented as follows: For subjects with baseline NRS scores ≥4, investigators administered the first PCIA bolus to initiate analgesia.The exact time of investigator's first PCIA activation was recorded as D0-0h. PCIA Pump Settings: Experimental Group: 2 mg per demand dose (2 mL/dose); Control Group: 1 mg per demand dose (2 mL/dose); Lockout Interval: 10 minutes. Background Infusion: None. Subsequent Analgesia Management: Following initial activation, subjects self-administered additional PCIA doses as needed based on pain levels. Subsequent PCIA Use: Subjects self-administer additional PCIA doses as needed based on pain levels. PCIA Discontinuation & Data Collection: At 48 hours (±20 min) after the first study drug administration (or upon early withdrawal), study staff will: pause and disconnect the PCIA pump, Record: total number of PCIA presses, number of effective presses and total dosage of study drug delivered via PCIA

  7. Time to First Use of Rescue Medication

    Time frame: 0-48 hours

    Time to first use of rescue medication during 0~48h.(For subjects with inadequate pain control (NRS score ≥4) who consent to rescue therapy, the following conditions must be met before administering rescue medication: 1) NRS score remains ≥4 within 5 minutes prior to rescue drug administration; 2) At least 5 minutes have elapsed since the last effective PCIA pump press, and the next PCIA bolus is not yet due)

  8. Proportion of Subjects Requiring Rescue Medication

    Time frame: 0-48 hours

  9. Number of Rescue Medication Administrations

    Time frame: 0-48 hours

  10. Proportion of Subjects with Treatment Failure

    Time frame: 0-48 hours

  11. Patient Global Impression of Change (PGIC) at 48 Hours Post-Dose

    Time frame: 0-48 hours

    The PGIC scale (6-point) will be administered at 48h (±30min) post-dose to evaluate patients' perceived change in analgesia, ranging from 'Very much improved' (1) to 'Much worse' (6).

Sponsors and collaborators

Lead sponsor

Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd

Industry

Registry information

Official study title

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase III Clinical Study to Evaluate the Efficacy and Safety of Nalbuphine Versus Morphine for the Treatment of Postoperative Analgesia

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Apr 29, 2025
Registry last updated
Jun 25, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.